SCHEMBL24317507

SCHEMBL24317507

O=C1CCCC(CN2C(=O)c3cccc4cccc2c34)C(=O)N1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.48
▸ HPGD P15428 2/20 0.48
▸ CASP1 P29466 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MPI P34949 1/20 0.48
▸ CACNA1B Q00975 1/20 0.48
▸ APBA1 Q02410 1/20 0.48
▸ POLB P06746 2/20 0.47
▸ KDM4E B2RXH2 4/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ UBE2N P61088 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ ATM Q13315 1/20 0.43
▸ CASP7 P55210 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ HTT P42858 1/20 0.40
▸ HEXA P06865 1/20 0.40
▸ HEXB P07686 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317649 0.77 CRBN (0.57) ALDH1A1TDP1
SCHEMBL7130966 0.76 ALDH1A1 (0.59) ALDH1A1HPGDCASP1SMN1; SMN2MPI
SCHEMBL7120833 0.75 POLB (0.60) ALDH1A1HPGDCASP1SMN1; SMN2MPI
SCHEMBL25123287 0.74 CRBN (0.59) ALDH1A1TDP1
SCHEMBL29774558 0.72 CRBN (0.68) ALDH1A1TDP1
SCHEMBL22532914 0.72 CRBN (0.68) ALDH1A1TDP1
SCHEMBL2175176 0.67 CRBN (0.78) ALDH1A1TDP1
SCHEMBL9720971 0.66 HPGD (0.70) ALDH1A1HPGDCASP1SMN1; SMN2MPI
SCHEMBL6270684 0.66 ALDH1A1 (1.00) ALDH1A1HPGDCASP1SMN1; SMN2MPI
SCHEMBL29437299 0.66 ALDH1A1 (1.00) ALDH1A1HPGDCASP1SMN1; SMN2MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 — — WO disclosed
Send feedback